Physician profile
Suma Pusapati
NPI 1902530710
$2,644.72
in general payments reported to CMS, 2019-2025
10 companies · $2,535 in 2025
The $2,535 reported for 2025 was more than what 87% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $59.45 · 2024: $50.43 · 2025: $2,535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $1,929 · Food and Beverage: $439 · Education: $277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $1,928.57 |
| Food and Beverage | $439.30 |
| Education | $276.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,347.72 | 2025 | Assurity, Thoratec Heartmate 3 Lvas Implant Kit, Ensite |
| Astrazeneca Pharmaceuticals LP | $60.95 | 2025 | |
| Abiomed | $44.86 | 2024-2025 | Impella |
| Boston Scientific Corporation | $40.13 | 2025 | General - Atherectomy |
| Genzyme Corporation | $39.06 | 2023 | |
| Novartis Pharmaceuticals Corporation | $30.20 | 2025 | |
| Averitas Pharma INC. | $23.29 | 2024 | Qutenza |
| Medtronic, INC. | $23.19 | 2025 | Symplicity G3 |
| Kyowa Kirin, INC. | $20.39 | 2023 | Poteligeo |
| Bayer Healthcare Pharmaceuticals INC. | $14.93 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suma Pusapati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.